August 05, 2026: Park Medi World Ltd. has reported a strong start to FY27, with robust growth across revenue, EBITDA and profit, driven by higher patient volumes, improved case mix and the impact of revised CGHS rates. Following the earnings, Emkay Research reiterated its ‘BUY’ rating and increased its target price to ₹375 from ₹350, implying an upside of over 32% from the current market price.
Author: Aadarsh Patel | EQMint
Q1 FY27 Financial Highlights
The hospital chain delivered healthy year-on-year growth during the June quarter:
- Revenue: ₹475.7 crore, up 19% YoY
- EBITDA: ₹126.1 crore, up 20% YoY
- EBITDA Margin: 26.5%
- PAT: ₹82.5 crore, up 31% YoY
- ARPOB Growth: 12% YoY
- In-patient Volume Growth: 16% YoY
- Out-patient Volume Growth: 17% YoY
The company also benefited from lower finance costs as debt reduced, supporting a sharp improvement in profitability.
Expansion Strategy Remains on Track
Park Medi World continues to expand aggressively through acquisitions and greenfield projects.
Key expansion highlights include:
- Acquisition of a hospital in Zirakpur, strengthening its Punjab Tricity cluster.
- Plans to add nearly 2,130 beds across FY27 and FY28.
- Around 1,800 additional beds expected over the next 18 months.
- Capex budget of approximately ₹767 crore for expansion.
Management expects the new hospitals in Rudrapur, Agra and Zirakpur to contribute meaningfully to revenue over the coming years.
Management Guidance
For FY27, management has guided for:
- Revenue Growth: 24%
- EBITDA Growth: 19%
- PAT Growth: 39%
The company expects higher occupancy, improved case mix and full-year benefits from revised CGHS rates to support growth.
Emkay Research Outlook
Emkay believes Park Medi World remains well-positioned for long-term growth because of:
- Strong hospital expansion pipeline.
- Improving profitability.
- Higher contribution from high-acuity procedures.
- Healthy balance sheet with net cash position.
- Expected 25% revenue CAGR between FY26 and FY29.
Based on these factors, Emkay has:
- Maintained: BUY Rating
- Revised Target Price: ₹375 (from ₹350)
- Current Market Price: ₹283
- Potential Upside: 32.5%
EQMint Analysis
Park Medi World has delivered another strong quarter while continuing one of the fastest expansion strategies among listed hospital chains. The combination of improving margins, expanding bed capacity and disciplined capital allocation provides visibility for sustained earnings growth.
While occupancy may remain under pressure in the short term due to rapid capacity additions, higher ARPOB, improving patient mix and new hospital ramp-ups could support profitability over the medium term.
Current View on Park Medi World Ltd.
Park Medi World continues to execute well on both operational performance and expansion. If management delivers on its FY27 guidance and successfully integrates its new hospitals, the company could remain one of the fastest-growing players in India’s healthcare sector.
For more such information visit EQMint
Join our Whatsapp channel for timely updates: Whatsapp
Disclaimer: This article is not an investment advice and is for educational purpose only.
